As described above, demonstrating superiority in OS, ABCP therapy has shown improved PFS and ORR in patients with EGFR-mutated NSCLC when administered within a selected patient group instead of ICI-free platinum-based combination regimens in daily clinical practice. Here, EGFR is linked to non-small cell lung carcinoma.